EU Regulator Grants Label Expansion for GlaxoSmithKline's Ovarian Cancer Therapy
On Thursday, GlaxoSmithKline (NYSE: GSK) announced that the European Commission had approved Zejula as a first-in-line therapy for adult patients who have ovarian, fallopian tube, or primary peritoneal cancer, following chemotherapy. The FDA approved the drug for the same indications back in April.
"Over 65,000 women in Europe are diagnosed with ovarian cancer each year," noted Dr. Hal Barron, the chief science officer at GlaxoSmithKline. "This approval of Zejula means that many more women will have the option to receive this innovative medicine earlier, potentially expanding the time they may spend without their devastating cancer progressing."
Image source: Getty Images
Source Fool.com
